Cryptococcus Species Other Than Cryptococcus neoformans and Cryptococcus gattii: Are They Clinically Significant?

被引:15
作者
Cano, Edison J. [1 ]
Yetmar, Zachary A. [1 ]
Razonable, Raymund R. [1 ]
机构
[1] Mayo Clin, Div Infect Dis, 200 First St SW, Rochester, MN 55905 USA
来源
OPEN FORUM INFECTIOUS DISEASES | 2020年 / 7卷 / 12期
关键词
Cryptococcus; fungal infection; immunocompromised host; mycology; non-neoformans; gattii; LAURENTII; PATIENT; LIQUEFACIENS; INFECTIONS; KERATITIS; DIFFLUENS;
D O I
10.1093/ofid/ofaa527
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Cryptococcus species other than C neoformans and C gattii rarely cause clinically significant or invasive disease. Background Cryptococcus spp is a major cause of opportunistic infections in immunocompromised patients, primarily due to Cryptococcus neoformans and Cryptococcus gattii. There are occasional reports of other Cryptococcus species causing invasive human disease. However, their epidemiology and clinical significance are not fully defined. We sought to describe cases with cultures positive for Cryptococcus species other than C neoformans and C gattii. Methods A retrospective descriptive analysis of clinical and laboratory data of patients with cultures growing Cryptococcus species other than C neoformans and C gattii from November 2011 to February 2019 was performed. Three Mayo Clinic sites in Arizona, Florida, and Minnesota were included. Results From 176 cases with a culture growing Cryptococcus spp, 54 patients (30%) had a culture for Cryptococcus other than C neoformans and C gattii in the study time frame. The most common species were Cryptococcus magnus, Cryptococcus laurentii, and Cryptococcus ater. The organisms were isolated and identified in culture of bronchoalveolar lavage (11), skin (11), urine (7), oral (4), sinus (3), intraoperative soft tissue (3), sputum (2), synovial fluid (2), cerebrospinal fluid (2), and intravenous catheter (2), among others (7). Only 8 (15%) cases were considered to be potentially pathogenic, with 1 case of invasive disease. Antifungal treatment was fluconazole, itraconazole, and griseofulvin, for a mean systemic antifungal duration of 42 days. Conclusions This large series of patients with Cryptococcus spp other than C neoformans and C gattii suggests that these species rarely cause clinically significant infection in humans. Only 1 case of invasive disease was found.
引用
收藏
页数:4
相关论文
共 50 条
  • [41] Molecular epidemiology of Cryptococcus neoformans and Cryptococcus gattii in China between 2007 and 2013 using multilocus sequence typing and the DiversiLab system
    Dou, H. -T.
    Xu, Y. -C.
    Wang, H. -Z.
    Li, T. -S.
    EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2015, 34 (04) : 753 - 762
  • [42] Evaluation of the Biofire FilmArray meningitis/encephalitis assay for the detection of Cryptococcus neoformans/gattii
    Van, T. T.
    Kim, T. H.
    Butler-Wu, S. M.
    CLINICAL MICROBIOLOGY AND INFECTION, 2020, 26 (10) : 1375 - 1379
  • [43] Cryptococcus neoformans infection in malignancy
    Schmalzle, Sarah A.
    Buchwald, Ulrike K.
    Gilliam, Bruce L.
    Riedel, David J.
    MYCOSES, 2016, 59 (09) : 542 - 552
  • [44] Ecoepidemiology of Cryptococcus gattii in Developing Countries
    Herkert, Patricia F.
    Hagen, Ferry
    Pinheiro, Rosangela L.
    Muro, Marisol D.
    Meis, Jacques F.
    Queiroz-Telles, Flavio
    JOURNAL OF FUNGI, 2017, 3 (04)
  • [45] Prediction of the Species Distribution of Cryptococcus neoformans Throughout Turkey
    Ergin, Cagri
    Sengul, Mustafa
    Dogen, Aylin
    ilkit, Macit
    MIKROBIYOLOJI BULTENI, 2019, 53 (02): : 233 - 238
  • [46] Altered Immune Response Differentially Enhances Susceptibility to Cryptococcus neoformans and Cryptococcus gattii Infection in Mice Expressing the HIV-1 Transgene
    Leongson, Kassandre
    Cousineau-Cote, Vincent
    Goupil, Mathieu
    Aumont, Francine
    Senechal, Serge
    Gaboury, Louis
    Jolicoeur, Paul
    Kronstad, James W.
    de Repentigny, Louis
    INFECTION AND IMMUNITY, 2013, 81 (04) : 1100 - 1113
  • [47] A murine model of Cryptococcus gattii meningoencephalitis
    Thompson, George R., III
    Wiederhold, Nathan P.
    Najvar, Laura K.
    Bocanegra, Rosie
    Kirkpatrick, William R.
    Graybill, John R.
    Patterson, Thomas F.
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2012, 67 (06) : 1432 - 1438
  • [48] Differential In Vitro Cytokine Induction by the Species of Cryptococcus gattii Complex
    Herkert, Patricia F.
    dos Santos, Jessica C.
    Hagen, Ferry
    Ribeiro-Dias, Fatima
    Queiroz-Telles, Flavio
    Netea, Mihai G.
    Meis, Jacques F.
    Joosten, Leo A. B.
    INFECTION AND IMMUNITY, 2018, 86 (04)
  • [49] Immune evasion by Cryptococcus gattii in vaccinated mice coinfected with C. neoformans
    Hester, Maureen M.
    Carlson, Diana
    Lodge, Jennifer K.
    Levitz, Stuart M.
    Specht, Charles A.
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [50] Cryptococcus neoformans and Cryptococcus gattii Species Complexes in Latin America: A Map of Molecular Types, Genotypic Diversity, and Antifungal Susceptibility as Reported by the Latin American Cryptococcal Study Group
    Firacative, Carolina
    Meyer, Wieland
    Castaneda, Elizabeth
    JOURNAL OF FUNGI, 2021, 7 (04)